Progyny (PGNY) Stock Price

Progyny Price

NASDAQ·CLOSED
25.61USD-2.62 (-9.73 %)
Market closed

Over the last 8 years Progyny grew revenue by 51.2% annually, reaching 1.29 B USD. Earnings per share have grown at 83.4% per year over the last 7 years. For Progyny, the net margin of 4.5% is down versus 13.1% a few years ago. The consensus 12-month price target for Progyny is 30.60 USD, about 19.5% above where the stock trades today. Of 17 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 57% above its 52-week low.

Progyny stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Progyny over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Progyny stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Progyny's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Progyny Stock Price History
DateProgyny Price
8/12/202625.61 USD
8/10/202628.23 USD
8/7/202628.10 USD
8/6/202630.21 USD
8/5/202631.74 USD
8/4/202631.42 USD
8/3/202631.53 USD
7/31/202631.13 USD
7/30/202631.49 USD
7/29/202631.38 USD
7/27/202631.66 USD
7/23/202630.70 USD
7/22/202631.35 USD
7/21/202632.24 USD
7/20/202631.77 USD
7/17/202631.93 USD
7/16/202631.86 USD
7/15/202632.34 USD
7/14/202632.36 USD
7/13/202631.66 USD
7/10/202630.65 USD
7/9/202631.07 USD
7/8/202630.68 USD
7/7/202630.78 USD
7/6/202629.99 USD
7/2/202630.22 USD
7/1/202629.45 USD
6/30/202628.83 USD
6/29/202628.36 USD
6/26/202628.51 USD
6/25/202627.38 USD
6/24/202626.89 USD
6/23/202626.63 USD
6/22/202626.79 USD
6/18/202626.11 USD
6/17/202626.53 USD
6/16/202626.81 USD
6/15/202626.93 USD
6/12/202625.93 USD
6/11/202625.75 USD
6/10/202625.57 USD
6/9/202625.83 USD
6/8/202625.92 USD
6/5/202625.70 USD
6/4/202625.88 USD
6/3/202624.87 USD
6/2/202625.81 USD
6/1/202626.26 USD
5/29/202625.78 USD
5/28/202625.58 USD
5/27/202625.46 USD
5/26/202625.38 USD
5/22/202624.97 USD
5/21/202624.78 USD
5/20/202625.36 USD
5/19/202624.60 USD
5/18/202624.05 USD
5/15/202623.25 USD
5/14/202622.87 USD
5/13/202623.51 USD
5/12/202623.45 USD
5/11/202622.55 USD
5/8/202623.72 USD
5/7/202619.16 USD
5/6/202618.70 USD
5/5/202618.98 USD
5/4/202618.91 USD
5/1/202618.60 USD
4/30/202618.58 USD
4/29/202618.42 USD
4/28/202618.38 USD
4/27/202618.41 USD
4/24/202618.17 USD
4/23/202617.67 USD
4/22/202617.99 USD
4/21/202618.02 USD
4/20/202618.64 USD
4/17/202618.12 USD
4/16/202617.93 USD
4/15/202617.39 USD
4/14/202617.17 USD
4/13/202616.98 USD
4/10/202616.30 USD
4/9/202616.53 USD
4/8/202616.93 USD
4/7/202617.16 USD
4/6/202616.78 USD
4/2/202616.60 USD
4/1/202616.86 USD
3/31/202616.98 USD
3/30/202616.97 USD
3/27/202617.27 USD
3/26/202617.79 USD
3/25/202617.75 USD
3/24/202618.05 USD
3/23/202618.01 USD
3/20/202618.13 USD
3/19/202618.18 USD
3/18/202617.87 USD
3/17/202618.05 USD
3/16/202617.42 USD
3/13/202617.50 USD
3/12/202617.50 USD
3/11/202617.51 USD
3/10/202617.91 USD
3/9/202618.25 USD
3/6/202618.31 USD
3/5/202617.62 USD
3/4/202617.79 USD
3/3/202617.52 USD
3/2/202617.60 USD
2/27/202617.69 USD
2/26/202622.25 USD
2/25/202621.33 USD
2/24/202620.78 USD
2/23/202621.31 USD
2/20/202620.98 USD
2/19/202620.76 USD
2/18/202620.36 USD
2/17/202620.35 USD
2/13/202620.69 USD
2/12/202620.98 USD
2/11/202621.55 USD
2/10/202621.52 USD
2/9/202621.65 USD
2/6/202621.95 USD
2/5/202621.92 USD
2/4/202622.77 USD
2/3/202623.24 USD
2/2/202624.21 USD
1/30/202623.87 USD
1/29/202624.12 USD
1/28/202624.53 USD
1/27/202624.25 USD
1/26/202624.84 USD
1/23/202625.22 USD
1/22/202625.00 USD
1/21/202625.45 USD
1/20/202625.38 USD
1/16/202624.52 USD
1/15/202624.31 USD
1/14/202626.12 USD
1/13/202625.24 USD
1/12/202628.42 USD
1/9/202626.99 USD
1/8/202627.43 USD
1/7/202626.80 USD
1/6/202626.67 USD
1/5/202626.66 USD
1/2/202625.74 USD
12/31/202525.68 USD
12/30/202525.84 USD
12/29/202525.62 USD
12/26/202525.80 USD
12/24/202525.51 USD
12/23/202525.57 USD
12/22/202526.96 USD
12/19/202526.63 USD
12/18/202526.16 USD
12/17/202525.99 USD
12/16/202526.01 USD
12/15/202526.34 USD
12/12/202526.71 USD
12/11/202526.01 USD
12/10/202525.17 USD
12/9/202524.72 USD
12/8/202524.70 USD
12/5/202524.02 USD
12/4/202524.15 USD
12/3/202524.55 USD
12/2/202524.95 USD
12/1/202525.27 USD
11/28/202526.37 USD
11/26/202526.70 USD
11/25/202526.77 USD
11/24/202526.33 USD
11/21/202525.86 USD
11/20/202524.83 USD
11/19/202525.40 USD
11/18/202525.85 USD
11/17/202526.82 USD
11/14/202524.55 USD
11/13/202524.42 USD
11/12/202524.07 USD
11/11/202523.81 USD
11/10/202523.62 USD
11/7/202522.37 USD
11/6/202518.01 USD
11/5/202518.88 USD
11/4/202518.57 USD
11/3/202518.43 USD
10/31/202518.71 USD
10/30/202518.65 USD
10/29/202519.09 USD
10/28/202519.23 USD
10/27/202519.53 USD
10/24/202519.49 USD
10/23/202519.50 USD
10/22/202519.17 USD
10/21/202519.41 USD
10/20/202519.63 USD
10/17/202519.34 USD
10/16/202521.33 USD
10/15/202520.32 USD
10/14/202520.23 USD
10/13/202520.43 USD
10/10/202520.10 USD
10/9/202520.57 USD
10/8/202520.58 USD
10/7/202520.00 USD
10/6/202520.19 USD
10/3/202520.59 USD
10/2/202520.55 USD
10/1/202521.22 USD
9/30/202521.52 USD
9/29/202521.42 USD
9/26/202521.46 USD
9/25/202521.36 USD
9/24/202521.70 USD
9/23/202521.47 USD
9/22/202522.13 USD
9/19/202521.62 USD
9/18/202522.52 USD
9/17/202521.63 USD
9/16/202521.77 USD
9/15/202522.13 USD
9/12/202522.51 USD
9/11/202523.17 USD
9/10/202522.63 USD
9/9/202522.97 USD
9/8/202522.85 USD
9/5/202522.55 USD
9/4/202523.56 USD
9/3/202523.54 USD
9/2/202523.41 USD
8/29/202523.67 USD
8/28/202523.25 USD
8/27/202523.02 USD
8/26/202522.64 USD
8/25/202523.14 USD
8/22/202523.53 USD
8/21/202523.13 USD
8/20/202522.56 USD
8/19/202522.74 USD
8/18/202523.78 USD
8/15/202523.40 USD
Access this data via the Eulerpool API
Get Free API Key

Progyny Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.08 B USD
62.18 M USD
62.04 M USD
Jan 1, 2024
1.17 B USD
67.46 M USD
54.34 M USD
Jan 1, 2025
1.29 B USD
85.28 M USD
58.52 M USD
Jan 1, 2026 (e)
1.38 B USD
141.78 M USD
178.92 M USD
Jan 1, 2027 (e)
1.51 B USD
154.22 M USD
195.94 M USD
Jan 1, 2028 (e)
1.58 B USD
161.74 M USD
141.38 M USD
Jan 1, 2029 (e)
1.70 B USD
173.67 M USD
169.40 M USD
Jan 1, 2030 (e)
1.68 B USD
172.54 M USD
150.87 M USD

Progyny Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 1:52 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
0.050.110.230.340.500.791.091.171.291.381.511.581.701.68
–118.75118.1050.2245.3557.2038.427.2610.376.919.594.577.41-0.65
14.5818.1019.6520.3522.4021.2521.8821.6823.6023.6023.6023.6023.6023.60
7.0019.0045.0070.00112.00167.00238.00253.00304.00325.01356.16372.45400.06397.47
-11.00-6.009.008.0032.0023.0062.0067.0085.00141.00154.00161.00173.00172.00
-22.92-5.713.932.336.402.935.705.746.6010.2410.2110.2010.2110.21
-12.00–-8.0046.0065.0030.0062.0054.0058.00178.00195.00141.00169.00150.00
–––-675.0041.30-53.85106.67-12.907.41206.909.55-27.6919.86-11.24
6.0070.5964.1999.02100.32100.06100.7595.4589.4689.4689.4689.4689.4689.46
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Progyny generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Progyny retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Progyny's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Progyny has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Progyny's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Progyny stock margins

The Progyny margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Progyny. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Progyny.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
22.42 %
6.47 %
13.15 %
Jan 1, 2022
21.26 %
2.97 %
3.86 %
Jan 1, 2023
22.05 %
5.74 %
5.73 %
Jan 1, 2024
21.71 %
5.78 %
4.66 %
Jan 1, 2025
23.63 %
6.62 %
4.54 %
Jan 1, 2026 (e)
23.63 %
10.30 %
12.99 %
Jan 1, 2027 (e)
23.63 %
10.22 %
12.98 %
Jan 1, 2028 (e)
23.63 %
10.25 %
8.96 %

Progyny Stock Revenue, EBIT, Earnings per Share

The Progyny earnings per share therefore indicates how much revenue Progyny has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
4.99 USD
0.32 USD
0.66 USD
Jan 1, 2022
7.86 USD
0.23 USD
0.30 USD
Jan 1, 2023
10.75 USD
0.62 USD
0.62 USD
Jan 1, 2024
12.23 USD
0.71 USD
0.57 USD
Jan 1, 2025
14.40 USD
0.95 USD
0.65 USD
Jan 1, 2026 (e)
15.97 USD
1.58 USD
2.08 USD
Jan 1, 2027 (e)
17.51 USD
1.72 USD
2.27 USD
Jan 1, 2028 (e)
18.31 USD
1.81 USD
1.64 USD

Progyny business model & stock analysis

Progyny Inc. is a company specializing in reproductive medicine and fertility treatments. It was founded in New York City in 2008 and has been listed on the NASDAQ stock exchange since 2019. The idea for Progyny arose when founder Gina Bartasi herself had difficulty getting pregnant and was searching for support and transparent information. She recognized the need to offer a better and more accessible service for people with fertility problems, thus founding Progyny. Progyny's business model is to offer employers a fertility benefit to help their employees, especially women, with family planning. It provides customized fertility treatments and financial assistance through its innovative programs. This allows employers to position themselves as progressive and inclusive while also increasing the bond and well-being of their employees. The different divisions of Progyny include fertility management, fertility measurement and monitoring, and fertility benefits. The fertility management solutions provide companies with comprehensive care for their employees, including counseling and support on fertility and family planning. They also provide access to an exclusive network practice specializing in reproductive medicine, including in vitro fertilization (IVF) and egg donation. The fertility measurement and monitoring program offers a personalized fertility profile that allows employees to track their fertility status to maximize their chances of a successful pregnancy. Progyny utilizes advanced methods of artificial intelligence and machine learning for this purpose. Progyny's fertility benefits include financial support for fertility treatments and medications that are not normally covered by health insurance. Additionally, the company offers a unique membership option that provides unlimited access to master fertility practices for one year. Progyny also offers a comprehensive patient experience through world-leading doctors and a patented technology platform. The platform provides support in navigating the fertility process and ensures that patients receive the best possible medical and financial care. Overall, Progyny has a significant impact on the field of reproductive medicine. With an innovative solution tailored to the needs of employers and strong support for aspiring parents, the company achieves a higher success rate in pregnancy compared to traditional fertility treatments. Progyny's technology platform improves workflow efficiency and communication in the practice, leading to a better patient experience and greater engagement. Overall, Progyny offers a holistic solution for employers and employees tailored to the unique challenges of family planning and fertility. With innovative approaches and a focus on the well-being of female employees, the company has taken a unique position in the market and is expected to continue to play a strong role in the industry.

Progyny SWOT Analysis

Strengths

Progyny Inc has established itself as a leader in the fertility benefits management industry, providing comprehensive solutions for employers and patients alike. The company's strengths lie in:

  • Advanced technology platform that streamlines the fertility treatment process
  • Strong network of top-tier fertility clinics and specialists
  • Patent-protected services and proprietary fertility medication discounts
  • Positive reputation and high customer satisfaction

Weaknesses

While Progyny Inc has several strengths, there are some areas where the company can improve:

  • Relatively high costs associated with fertility treatments may limit market reach
  • Dependency on employer-funded contracts, which can be affected by economic fluctuations
  • Limited international expansion, focusing primarily on the United States market

Opportunities

Progyny Inc can capitalize on various opportunities in the fertility benefits management sector:

  • Increasing awareness and acceptance of fertility treatments, fueling market growth
  • Expansion into international markets with high demand for fertility services
  • Potential partnerships with insurance providers to broaden coverage options
  • Advancements in reproductive technologies, opening up new treatment possibilities

Threats

As with any business, Progyny Inc faces certain threats that could impact its operations:

  • Competition from other fertility benefits management companies, leading to potential market saturation
  • Changes in government regulations and healthcare policies that may affect reimbursement and coverage
  • Economic downturns impacting employer-based funding for fertility treatments

Progyny Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Progyny Employees
Details
Date
Progyny Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Progyny Segments

Progyny Revenue by Segment (1/2)

  • Max

Fertility benefit services revenue
Pharmacy benefit services revenue
Details
Date
Fertility benefit services revenue
Pharmacy benefit services revenue
Jan 1, 2025
830.93 M USD
457.73 M USD

Progyny Revenue by Segment (2/2)

  • Max

Reportable segment
Details
Date
Reportable segment
Jan 1, 2025
1.29 B USD

Progyny Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Progyny historical P/E ratio, EBIT multiple, and P/S ratio

Progyny annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Progyny shares outstanding

The number of shares of Progyny was 89.46 M in 2025. This indicates how many shares Progyny is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
100.32 M Stocks
Jan 1, 2022
100.06 M Stocks
Jan 1, 2023
100.75 M Stocks
Jan 1, 2024
95.45 M Stocks
Jan 1, 2025
89.46 M Stocks
Jan 1, 2026 (e)
89.46 M Stocks
Jan 1, 2027 (e)
89.46 M Stocks
Jan 1, 2028 (e)
89.46 M Stocks

Current Progyny forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
82.35 % (14)
Hold
17.65 % (3)
Sell
0.00 % (0)
12M Price Target
30.60
Last Price
25.89
Currency
USD
12M Return Potential
18.19 %
LTM Return
0 %

Progyny Analyst Rating Actions

DateFirmActionRatingReliability
7/28/2026
Barclays
Barclays
DowngradeOverweightEqual Weight33
7/24/2026
BTIG
BTIG
MaintainedBuy–
7/21/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/13/2026
Keybanc
Keybanc
MaintainedOverweight49
6/22/2026
Truist Securities
Truist Securities
MaintainedBuy–
6/2/2026
B of A Securities
B of A Securities
MaintainedBuy70
5/19/2026
Canaccord Genuity
Canaccord Genuity
UpgradeHoldBuy59
5/18/2026
Barclays
Barclays
MaintainedOverweight33
5/11/2026
Truist Securities
Truist Securities
MaintainedBuy–
5/11/2026
Citizens
Citizens
MaintainedMarket Outperform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Progyny Earnings Calls

2025

Progyny Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/20260.34USD-355.66 MUSD-2026 Q2
5/7/20260.30USD-333.10 MUSD-2026 Q1
3/2/20260.15USD-313.60 MUSD-2025 Q4
8/7/20250.17USD-326.48 MUSD-2025 Q2
11/12/20240.14USD-302.82 MUSD-2024 Q3
5/6/20240.19USD-318.76 MUSD-2024 Q1
2/26/20240.10USD-279.13 MUSD-2023 Q4
8/2/20230.12USD-268.31 MUSD-2023 Q2
5/3/20230.09USD-241.27 MUSD-2023 Q1
2/27/20230.00USD-211.47 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Progyny stock

31/100
10
Environment
53
Social
31
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Progyny shareholder structure

% Name
13.91772%
BLACKROCK, INC.
BLACKROCK, INC.
7.54068%
FMR LLC
FMR LLC
6.13853%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.03821%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
3.57301%
STATE STREET CORP
STATE STREET CORP
3.27727%
AMERIPRISE FINANCIAL INC
AMERIPRISE FINANCIAL INC
...

Progyny Beneficial Ownership Filings (SEC 13D/G)

Free Float
91.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
24.40%
TPG Group Holdings (SBS) Advisors, Inc.
TPG Group Holdings (SBS) Advisors, Inc.
SEC ↗
24.40%
James G. Coulter
James G. Coulter
SEC ↗
24.40%
David Bonderman
David Bonderman
SEC ↗
17.50%
2
2
SEC ↗
15.50%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
13.00%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
11.60%
Winkelried
Winkelried
SEC ↗
11.60%
GP A, LLC
GP A, LLC
SEC ↗
11.60%
G. Coulter
G. Coulter
SEC ↗
11.60%
Bonderman
Bonderman
SEC ↗

Progyny Executives and Management Board

14 members · avg. age 62 · 29 % women

MS

Mr. Michael Sturmer (48)

President

21.53 M USD

Management

ML

Mr. Mark Livingston (59)

Chief Financial Officer

2.14 M USD
AS

Ms. Allison Swartz (36)

Executive Vice President, General Counsel, Secretary

1.93 M USD
PA

Mr. Peter Anevski (57)

Chief Executive Officer, Director · since 2017

1.36 M USD
MC

Ms. Melissa Cummings

Chief Operating Officer

–
GC

Mr. Geoffrey Clapp

Chief Product Officer

–

Board of Directors

JP

Mr. Jeffrey Park (53)

Lead Independent Director

609,386.00 USD
NP

Dr. Norman Payson (76)

Independent Director

567,299.00 USD
LD

Mr. Lloyd Dean (74)

Independent Director

518,326.00 USD
KG

Mr. Kevin Gordon (62)

Independent Director

518,326.00 USD
RH

Mr. Roger Holstein (72)

Independent Director

518,326.00 USD
CS

Ms. Cheryl Scott (75)

Independent Director

518,326.00 USD

Frequently asked questions about Progyny

Progyny Inc. is a leading fertility benefits management company. Their business model revolves around providing comprehensive fertility benefits to individuals and employers. Progyny's services include personalized care coordination, expert medical guidance, and access to a wide network of fertility specialists. By partnering with Progyny, individuals and employers are able to navigate the complex fertility landscape with ease, gaining access to innovative treatments and technologies. With a strong focus on patient outcomes and cost containment, Progyny aims to enhance the fertility journey for all involved parties. Through their unique business model, Progyny strives to empower individuals, improve outcomes, and build a more inclusive future for fertility care.

Progyny Inc is primarily active in the healthcare industry.

Progyny Inc faces competition from other companies in the fertility benefits industry such as Carrot, WINFertility, and Future Family. These companies provide similar services and solutions for infertility treatments and family-building support. However, Progyny Inc distinguishes itself by offering a comprehensive and personalized approach to fertility benefits, leveraging data analytics and providing access to a nationwide network of fertility specialists. With its innovative solutions and strategic partnerships, Progyny Inc stands out as a leading player in the market, committed to empowering individuals and couples on their journey to parenthood.

Progyny Inc. is a prominent fertility benefits management company headquartered in New York. Established in 2015, Progyny offers comprehensive fertility solutions to employers and their employees, aiming to simplify and enhance the fertility journey. With a mission to make advancements in reproductive medicine accessible to a wider population, Progyny combines innovative technology, personalized care, and financial options to cater to diverse fertility needs. This company has successfully partnered with a vast network of world-class fertility specialists and providers to deliver exceptional outcomes. Progyny Inc. continues to play a crucial role in revolutionizing fertility benefits and ensuring that individuals can pursue their dreams of starting a family smoothly.

Progyny Inc has achieved several significant milestones since its inception. The company has successfully established itself as a leader in fertility benefits management, offering comprehensive solutions to employers and individuals. Progyny Inc has rapidly expanded its network of fertility clinics and providers, ensuring a wide range of options for patients. With a focus on personalized care and cutting-edge technology, Progyny Inc has helped thousands of individuals and couples navigate their fertility journeys. The company's commitment to research and innovations in reproductive medicine has further solidified its position in the industry. Progyny Inc continues to make strides towards revolutionizing fertility care and supporting individuals in building their families.

Progyny Inc is primarily present in the United States.

Progyny Inc represents a strong commitment to reproductive health and family building. The company's corporate philosophy revolves around providing comprehensive fertility benefits and exceptional patient care. Progyny Inc strongly believes in empowering individuals and couples to make informed decisions about their fertility journeys. Their values include compassion, integrity, innovation, and a dedication to improving the lives of individuals struggling with infertility. Progyny Inc's mission is to ensure cost-effective, high-quality fertility solutions and support, helping individuals and families achieve their dream of having a baby.

Analysts currently set an average price target of 30.79 USD for the Progyny stock (median: 30.60 USD), implying +18.9 % versus the latest price. The consensus is based on 17 analyst ratings.

Progyny Analyst Price Targets 2026

17 analysts currently rate the Progyny stock: 14 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Progyny to generate revenue of 1.38 B USD and earnings per share of 2.00 USD.

Progyny Analyst Price Targets 2026

Converted at the current exchange rate, the Progyny share trades at 22.21 EUR (25.61 USD).

The Progyny share (PGNY) is listed on 1 stock exchanges, including: NASDAQ (PGNY).

Progyny Inc is a leading healthcare company specializing in fertility treatments and services. The company was founded in 2008 and is headquartered in New York City. Progyny offers a comprehensive range of services to its customers, ranging from diagnosis to family support. Progyny provides its customers with personalized fertility programs that consider both medical and psychological aspects. The program begins with a comprehensive diagnosis and counseling to determine where the customer is on the fertility spectrum and what treatment options are available to them. Then, a treatment plan tailored to the specific needs of the customer is created. Progyny works with a range of doctors and clinics to ensure that its customers receive the best available treatment. An important part of Progyny's business model is its fertility network. The company has partnership agreements with over 500 fertility clinics and centers nationwide, producing over 2,000 success stories per year. Thanks to its network, Progyny has the ability to offer its customers comprehensive access to diagnostic and therapeutic services to achieve a successful pregnancy. Progyny also offers an online platform that facilitates customer access to its services. The website and mobile app provide a user-friendly interface for customers to view their lab results and medical records, as well as manage their treatment plans. Additionally, the platform provides a comprehensive collection of resources and information on fertility. Another key component of Progyny's offering is its financing options. Fertility treatments can be expensive, and many insurance plans do not cover them. However, Progyny has developed its own financing tools to help customers bear the costs of treatment. The company offers flexible financing options, discounts for self-pay patients, and a special membership, among other options. Progyny aims to provide a comprehensive suite of services that meet the needs and desires of its customers. The company focuses on delivering cutting-edge technologies to improve the success rate of fertility treatments, as well as an unmatched customer experience. Progyny strives to be a reliable partner for its customers, supporting them at every step of their fertility journey.

The expected revenue of Progyny is 1.38 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Progyny is 178.92 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Progyny is currently 12.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Progyny stock.

The price-to-sales ratio (P/S) of Progyny is currently 1.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Progyny stock.

The Eulerpool Quality Score for Progyny is 4/10.

The ISIN of Progyny is US74340E1038. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Progyny is A2PT5Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Progyny is PGNY. The ticker symbol is used to trade Progyny shares on the stock exchange.

Progyny paid dividends every year for the past 0 years.

Progyny is assigned to the 'Health' sector.

The dividends of Progyny are distributed in USD.

All fundamentals and in-depth analysis of Progyny

Our stock analysis for Progyny stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Progyny. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Progyny Stock
Progyny Revenue→
Progyny Stock
Progyny Net Income→
Progyny Stock
Progyny P/E→
Progyny Stock
Progyny P/S→
Progyny Stock
Progyny EBIT→
Progyny Stock
Progyny Dividend→
Progyny Stock
Progyny Directors Dealings→
Progyny Stock
Progyny Stocks→
Progyny Stock
Progyny Market capitalization→
Progyny Stock
Progyny Debt→
Progyny Stock
Progyny Liabilities→
Progyny Stock
Progyny Equity→
Progyny Stock
Progyny AAQS→
Progyny Stock
Progyny Employees→
Progyny Stock
Progyny ROE→
Progyny Stock
Progyny ROA→
Progyny Stock
Progyny ROCE→
Progyny Stock
Progyny News→
Progyny Stock
Progyny Analyst Price Targets→

Health Stocks

ProkidneyProfile SolutionsPromimicProfessional Medical Expertise Company SJSCProMIS NeurosciencesProfarma Distribuidora de Produtos FarmaceuticosPromisia HealthcareProdia Widyahusada Tbk PTPropanc BiopharmaProcyonProphase LabsProcter & Gamble HealthAll Stocks A–Z →